JPM movers: ImmunityBio rises to the top

For companies presenting at the J.P. Morgan Healthcare Conference, upbeat clinical and regulatory readouts in the past week pushed share prices up for a dozen companies, with ImmunityBio topping the list.

Sharing a first-in-human readout Friday, ImmunityBio Inc. (NASDAQ:IBRX) said CD19 t-haNK, an off-the-shelf allogeneic CD19 CAR-NK cell therapy, in combination with rituximab led to a durable complete response of 15 months for four patients with Waldenstrom non-Hodgkin lymphoma. The news sent shares to $5.52, up 137% from last Friday’s close of $2.33 for a rise in market cap of nearly $3.8 billion...